High incidence of atrial fibrillation in patients treated with ibrutinib

OBJECTIVE: Atrial fibrillation (AF) is one of the most common side effects of ibrutinib, a drug that has dramatically improved the prognosis of chronic B-cell malignancies such as chronic lymphocytic leukaemia (CLL). The true incidence of ibrutinib-related AF (IRAF) is not well known and its therape...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Open Heart
Glavni autori: Baptiste, Florian, Cautela, Jennifer, Ancedy, Yan, Resseguier, Noémie, Aurran, Thérèse, Farnault, Laure, Escudier, Marion, Ammar, Chloé, Gaubert, Mélanie, Dolladille, Charles, Barraud, Jeremie, Peyrol, Michael, Cohen, Ariel, Paganelli, Franck, Alexandre, Joachim, Ederhy, Stephane, Thuny, Franck
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2019
Teme:
Arrhythmias and Sudden Death
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6519413/
https://ncbi.nlm.nih.gov/pubmed/31168393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/openhrt-2019-001049
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items